Literature DB >> 36122414

2022 American Society of Clinical Oncology (ASCO): Meeting highlights.

Peter C Black1, Nazanin Fallah-Rad2, Andrew Loblaw3, Elie Kassouf4, Mira Keyes5, Naveen S Basappa6, Anand Swaminath7.   

Abstract

Entities:  

Year:  2022        PMID： 36122414      PMCID： PMC9484749          DOI： 10.5489/cuaj.8097

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   2.052


× No keyword cloud information.
  10 in total

1.  [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Authors:  Michael S Hofman; Louise Emmett; Shahneen Sandhu; Amir Iravani; Anthony M Joshua; Jeffrey C Goh; David A Pattison; Thean Hsiang Tan; Ian D Kirkwood; Siobhan Ng; Roslyn J Francis; Craig Gedye; Natalie K Rutherford; Andrew Weickhardt; Andrew M Scott; Sze-Ting Lee; Edmond M Kwan; Arun A Azad; Shakher Ramdave; Andrew D Redfern; William Macdonald; Alex Guminski; Edward Hsiao; Wei Chua; Peter Lin; Alison Y Zhang; Margaret M McJannett; Martin R Stockler; John A Violet; Scott G Williams; Andrew J Martin; Ian D Davis
Journal:  Lancet       Date:  2021-02-11       Impact factor: 79.321

2.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

3.  Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Authors:  Matthew R Smith; Maha Hussain; Fred Saad; Karim Fizazi; Cora N Sternberg; E David Crawford; Evgeny Kopyltsov; Chandler H Park; Boris Alekseev; Álvaro Montesa-Pino; Dingwei Ye; Francis Parnis; Felipe Cruz; Teuvo L J Tammela; Hiroyoshi Suzuki; Tapio Utriainen; Cheng Fu; Motohide Uemura; María J Méndez-Vidal; Benjamin L Maughan; Heikki Joensuu; Silke Thiele; Rui Li; Iris Kuss; Bertrand Tombal
Journal:  N Engl J Med       Date:  2022-02-17       Impact factor: 91.245

4.  Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.

Authors:  Chad Tang; Pavlos Msaouel; Kieko Hara; Haesun Choi; Venus Le; Amishi Y Shah; Jennifer Wang; Eric Jonasch; Seungtaek Choi; Quynh-Nhu Nguyen; Prajnan Das; Surendra Prajapati; Zhiqian Yu; Khaja Khan; Steven Powell; Ravi Murthy; Kanishka Sircar; Nizar M Tannir
Journal:  Lancet Oncol       Date:  2021-10-28       Impact factor: 41.316

5.  A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.

Authors:  Simon J Crabb; Syed Hussain; Eileen Soulis; Samantha Hinsley; Laura Dempsey; Avril Trevethan; YeePei Song; Jim Barber; John Frew; Joanna Gale; Guy Faust; Susannah Brock; Ursula McGovern; Omi Parikh; Deborah Enting; Santhanam Sundar; Gihan Ratnayake; Kathryn Lees; Alison J Birtle; Thomas Powles; Robert J Jones
Journal:  J Clin Oncol       Date:  2022-08-12       Impact factor: 50.717

6.  Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.

Authors:  Weijie Gu; Weiqing Han; Hong Luo; Fangjian Zhou; Dalin He; Lulin Ma; Hongqian Guo; Chaozhao Liang; Tie Chong; Jun Jiang; Zhiwen Chen; Yong Wang; Qing Zou; Ye Tian; Jun Xiao; Jian Huang; Shaoxing Zhu; Qiang Dong; Xiaoping Zhang; Hanzhong Li; Xinfeng Yang; Chunxia Chen; Junliang Li; Chunlei Jin; Xiaojing Zhang; Dingwei Ye
Journal:  Lancet Oncol       Date:  2022-09-05       Impact factor: 54.433

7.  Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.

Authors:  Christian Pfister; Gwenaelle Gravis; Aude Fléchon; Christine Chevreau; Hakim Mahammedi; Brigitte Laguerre; Aline Guillot; Florence Joly; Michel Soulié; Yves Allory; Valentin Harter; Stéphane Culine
Journal:  J Clin Oncol       Date:  2022-03-07       Impact factor: 50.717

8.  Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.

Authors:  Martin R Stockler; Andrew J Martin; Ian D Davis; Haryana M Dhillon; Stephen D Begbie; Kim N Chi; Simon Chowdhury; Xanthi Coskinas; Mark Frydenberg; Wendy E Hague; Lisa G Horvath; Anthony M Joshua; Nicola J Lawrence; Gavin M Marx; John McCaffrey; Ray McDermott; Margaret McJannett; Scott A North; Francis Parnis; Wendy R Parulekar; David W Pook; M Neil Reaume; Shahneen Sandhu; Alvin Tan; Thean Hsiang Tan; Alastair Thomson; Francisco Vera-Badillo; Scott G Williams; Diana G Winter; Sonia Yip; Alison Y Zhang; Robert R Zielinski; Christopher J Sweeney
Journal:  J Clin Oncol       Date:  2021-12-20       Impact factor: 50.717

9.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245

10.  Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.

Authors:  Alison Birtle; Mark Johnson; John Chester; Robert Jones; David Dolling; Richard T Bryan; Christopher Harris; Andrew Winterbottom; Anthony Blacker; James W F Catto; Prabir Chakraborti; Jenny L Donovan; Paul Anthony Elliott; Ann French; Satinder Jagdev; Benjamin Jenkins; Francis Xavier Keeley; Roger Kockelbergh; Thomas Powles; John Wagstaff; Caroline Wilson; Rachel Todd; Rebecca Lewis; Emma Hall
Journal:  Lancet       Date:  2020-03-05       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.